Medically reviewed by Jacque Lovely, RN MN MBA PMP Reg# 74334 | Head of Western Operations at ATMA CENA
This FAQ answers the questions Canadian clinicians most often ask about psychedelic-assisted therapy (PAT) training: who can train, what each profession can legally do, how ketamine differs from psilocybin and MDMA, how training counts toward continuing education, and what happens after you finish. Each answer is current as of May 2026 — verify any regulatory point with your provincial college before acting on it.
Key takeaways
- Training itself is legal for any clinician. What you can legally do after training depends on your profession and province.
- Only physicians and nurse practitioners prescribe ketamine off-label and submit SAP requests for psilocybin and MDMA. Other regulated clinicians deliver the psychotherapy components.
- Ketamine-assisted therapy is the most accessible context today because no SAP application is required. Psilocybin and MDMA remain SAP-only and case-by-case.
- PAT training counts toward most colleges’ continuing-education requirements when it is relevant and documented.
- Personal psychedelic experience is not a regulatory prerequisite to train in Canada.
Not sure which pathway fits your licence? Book a call with our Program Advisor and an we can walk you through eligibility, CE recognition, and starting points.
Frequently Asked Questions
Is psychedelic therapy training legal in Canada?
Yes. Completing training is legal for any clinician, regardless of profession or province. Training teaches the pharmacology, safety, and psychotherapy skills used in psychedelic-assisted therapy. What changes by profession and province is what you can legally do afterward. A training certificate is not a licence to practise — your provincial regulatory college determines your scope. There is no nationally regulated psychedelic-therapist credential in Canada as of May 2026, so training functions as documented professional development and competency evidence, not as legal authorization to administer any substance.
Do I need to be a licensed clinician to enrol?
For roles that involve delivering psychedelic-assisted therapy within a clinical team, yes. The therapy components require an active provincial registration as a physician, nurse practitioner, psychologist, psychotherapist, registered counsellor, social worker, or nurse. Foundational and integration-focused training is open more broadly, including to wellness practitioners who provide preparation and integration support outside the dosing context. Without a regulated provincial credential, you cannot serve as a therapist of record on a psychedelic-assisted therapy team, whatever program you complete.
Which professions can train, and what can each one do?
Physicians and nurse practitioners can prescribe ketamine off-label, lead medical screening, and submit SAP requests for psilocybin and MDMA. Registered psychologists, registered psychotherapists, registered counsellors, registered social workers, and nurses deliver the psychotherapy components: preparation, in-session support, and integration. None of the non-prescribing professions can prescribe, administer, or possess a controlled substance, or submit an SAP application. Psychologists additionally bring formal assessment and outcome-measurement expertise.
Can a counsellor or psychotherapist do psychedelic therapy in Canada?
Yes, within scope and as part of an authorized team. Registered Psychotherapists in Ontario and permit-holding psychothérapeutes in Quebec can lead preparation, in-session support, and integration psychotherapy under a prescribing physician’s oversight. Registered counsellors can provide preparation and integration support and team-based dosing support within SAP-authorized or clinical-trial settings. Neither can prescribe, administer, or submit SAP applications. CRPO is in the process of developing guidance on the legal frameworks for psychedelic-assisted therapy, with no finalized comprehensive standard as of May 2026.
Can a psychologist do psychedelic-assisted therapy in Alberta?
Yes, within the limits set by the College of Alberta Psychologists in its June 2025 guideline. Alberta psychologists provide preparation and integration psychotherapy and must obtain specialized training first. Prescribing and diagnosing the need for psychedelic treatment sit outside psychological scope. Dosing must occur in a CPSA-accredited facility under a psychiatrist, or a physician in consultation with a psychiatrist. Alberta also restricts providers to six named regulated colleges, so unregulated counselling therapists are not in scope.
Is ketamine-assisted therapy legal, and how is it different from psilocybin or MDMA?
Ketamine is a Health Canada-approved anaesthetic. Psychiatric use is off-label and legal across provinces, regulated by provincial medical regulators. No SAP application is required, which makes ketamine-assisted therapy the most accessible context after training. Psilocybin and MDMA are restricted drugs accessible only through Health Canada’s Special Access Program on a case-by-case basis — a prescribing physician or nurse practitioner must submit each request.
Can I train in psilocybin or MDMA therapy before they are fully approved?
Yes. Training is legal regardless of a substance’s approval status. For psilocybin and MDMA, training prepares you to work within Health Canada’s SAP framework or in clinical trials — not for routine clinical practice outside those channels. Practice still requires per-patient SAP authorization submitted by a prescriber, and approvals are not guaranteed. The Psychedelic Association of Canada documented approximately half as many SAP approvals year over year as of September 2025, so the immediate clinical opportunity for most trainees is in ketamine-assisted therapy.
Do I need a personal psychedelic experience to train?
No. Personal psychedelic experience is not a formal prerequisite for training in Canada, and Health Canada SAP protocols do not require it. Some programs offer optional experiential components and others do not. A peer-reviewed argument that firsthand experience is a competency-relevant training element exists (Dames et al., 2024), but it represents one position in an active professional discussion rather than a settled clinical standard or regulatory requirement.
What prerequisites do I need before starting?
Active provincial college registration in your profession, plus relevant clinical experience. Training programs commonly expect one to two years of post-licensure experience for non-prescribing clinicians and two to five years post-residency for prescribers, with grounding in trauma-informed care, treatment-resistant depression, or PTSD. Nurse practitioners who intend to prescribe controlled substances complete their nursing college’s controlled-substances module first.
Does the training count for continuing-education credits?
Generally yes, when the program is relevant to your practice and properly documented. Requirements vary by regulator:
| Regulator | CE requirement |
|---|---|
| RCPSC (Royal College) | 400 MOC credits per 5-year cycle |
| CFPC (family physicians) | 250 Mainpro+ credits per 5-year cycle |
| CRPO (Ontario psychotherapists) | 40 hours per 2-year cycle |
| OPQ (Quebec psychologists) | 90 hours per 5-year period |
| CCPA (counsellors) | 36 hours per 3-year period |
| CPBAO (Ontario psychologists) | 50 hours per 2-year cycle |
ATMA CENA’s confirmed CE credit values per course: Foundations 14 credits; Applied Clinical Practice 46 credits; Prescribing & Oversight 40 credits; Advanced Safety & Support Practices 38 credits; Supervised Learning Lab 8 credits. KAT Immersive CE approval is pending. Confirm recognition with your specific college before enrolling.
Is there a national or standardized psychedelic-therapist credential?
No. As of May 2026, Canada has no nationally regulated psychedelic-therapist credential. Provincial regulatory colleges each determine scope and competence requirements. This is why training programs frame their certificates as documented competency development rather than as a licence, and why verifying requirements with your own college matters.
What does training cost in Canada?
ATMA CENA’s confirmed 2026 prices: Foundations $800; Applied Clinical Practice $4,200; Prescribing & Oversight $4,000; Advanced Safety & Support Practices $3,500; Supervised Learning Lab $1,000; KAT Immersive $2,400. Pathway bundles with a 10% discount: Clinical Pathway $5,400; Prescriber Pathway $4,320; Integrative Pathway $3,870. Payment plans available: 2-month and 3-month options. For a full breakdown, see Psychedelic Therapy Training Cost in Canada.
How long does training take?
Most pathways run several months part-time, combining asynchronous online modules with scheduled live sessions and supervised practice. Training is only one part of the timeline — confirming provincial registration and arranging a prescriber partnership also take time. For a step-by-step view, see How to Become a Psychedelic Therapist in Canada.
What is a supervised practicum, and do I need one?
A supervised practicum is structured, observed practice where you apply session skills with feedback from experienced supervisors, usually in a small-group or paired format. It bridges classroom learning and independent clinical work. Health Canada’s December 2022 risk-management expectations describe a minimum of two therapists present during dosing, with at least one licensed to provide psychotherapy — which is why training clinicians in supervised cohorts matters.
Which ATMA CENA pathway is right for me?
Physicians and nurse practitioners fit the Prescriber Pathway. Psychologists, psychotherapists, and counsellors who will deliver therapy fit the Clinical Pathway. Clinicians and wellness practitioners focused on preparation and integration outside the dosing context fit the Integrative Pathway. All three begin with the Foundations course. For a side-by-side comparison, see Which Psychedelic Therapy Training Pathway Is Right for Me?
What happens after I finish training?
Trained clinicians join PAT delivery through clinical-trial sites, SAP-authorized programs led by a prescribing physician, or structured clinic-network models. Independent practice still requires a prescribing physician or nurse practitioner partner for any context where a substance is administered. Before active practice, put documentation, informed consent arrangements, supervision arrangements, and professional liability coverage that explicitly includes PAT in place.
What is ATMA CENA’s CoCare program, and how does it connect to training?
CoCare is ATMA CENA’s collaborative-care model. Trained clinicians can deliver preparation and integration psychotherapy with their own clients while ATMA CENA’s clinical infrastructure handles ketamine prescribing and medically supervised dosing — so you do not have to build a standalone clinic. Network membership requires completion of Clinical Pathway training. The current per-province eligibility map by designation is pending confirmation — see how CoCare works or confirm at intake.
Compliance Disclaimer
Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators — for example, CPSA in Alberta, CPSM in Manitoba, and CPSO in Ontario.
Psilocybin and MDMA are restricted drugs under Canada’s Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada’s Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD. Completion of any training program does not constitute authorization to administer psilocybin or MDMA — SAP applications must be submitted by an authorized prescriber.
Regulated clinicians work within their provincial scope. Non-prescribing professions cannot prescribe, administer, or possess controlled substances. This article is educational and is not a clinical recommendation for any individual.
About the Author
Reverdi Darda RN, BScN Reg # 61707 | CEO & Founder, ATMA CENA
Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.
Medically reviewed by Jacque Lovely, RN MN MBA PMP Reg# 74334| Head of Western Operations at ATMA CENA
Sources
- College of Registered Psychotherapists of Ontario. Psychedelic-Assisted Psychotherapy Resource.
- College of Alberta Psychologists (2025). Psychedelic-Assisted Psychotherapy Practice Guideline (June 2025).
- College of Physicians and Surgeons of Alberta (2026). Ketamine Prescribing, Administration and Oversight Expectations (March 2026).
- Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy.
- Health Canada (2022). Expectations for risk-management measures for clinical trials involving psychedelic-assisted psychotherapy.
- Psychedelic Association of Canada (2025). Sharp decline in Health Canada SAP approvals (September 2025).
- CPSM (2026). Ketamine: What Prescribers and Pharmacists Need to Know (January 2026).
- OPQ / Légis Québec. Regulation respecting the psychotherapist’s permit (C-26, r. 222.1) (current January 1, 2026).
- Canadian Psychological Association. Continuing Education Approval Programme.
- Drozdz, S.J. et al. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15, 1691–1706.
- Dames, S. et al. (2024). Firsthand experience as a training element in psychedelic-assisted therapy. Psychedelic Medicine.
